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Abstract
Legalization of marijuana use will increase the number of people who will
become long-term users. A prior medical record review study in Australia, in
2004, identified 19 chronic marijuana users who entered the emergency
department with recurrent vomiting associated with abdominal pain. Routine
treatment of the nausea and vomiting, associated with the chronic marijuana
abuse, with antiemetics is ineffective in patients with cannabinoid
hyperemesis syndrome. Narcotics do not relieve the abdominal pain but may
cause worsening rebound pain. The best treatment of cannabinoid
hyperemesis syndrome was found to be abstinence from the recreational use
of marijuana. It is important for advanced practice nurses to place
cannabinoid hyperemesis syndrome in their differentials of patients
presenting to the emergency department with recurrent nausea, vomiting,
and abdominal pain. They need to be knowledgeable about cannabinoid
hyperemesis syndrome to provide the proper management of care for this
specific medical condition.

Legalization of marijuana use will increase the number of people
who will become long-term users. A prior medical record review study
in Australia, in 2004, identified 19 chronic marijuana users who
entered the emergency department with recurrent vomiting
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associated with abdominal pain. In the study, long-term users were
identified as those persons using marijuana on a daily basis or
monthly. The symptoms improved after taking hot showers or hot
baths. The hot showers and baths likely worked to correct the
disequilibrium of the thermoregulatory system of the hypothalamus
affected by the chronic marijuana use (Allen, DeMoore, Heddle, &
Twartz, 2004). Usually, the patients did not associate the use of
marijuana for precipitating the symptoms of nausea, vomiting, and
abdominal pain (Allen et al., 2004). With more recent research, these
symptoms of recurrent nausea, vomiting, and abdominal pain have
been identified as a medical condition named cannabinoid
hyperemesis syndrome (CHS). The triad of symptoms of CHS is
identified in recent studies as nausea, vomiting, and abdominal pain,
relieved by taking hot baths or showers (Simonetto, Oxentenko,
Herman, & Szostek, 2012; Sontineni, Chaudhary, Sontineni, &
Lanspa, 2009; Soriano-Co, Batke, & Cappell, 2010; Sun &
Zimmerman, 2013). These studies supported the findings of Allen et
al.'s (2004) study. Literature further identifies three phases of cyclic
vomiting: prodromal, hyperemetic, and the recovery phase (Galli,
Sawaya, & Friedenberg, 2011). Routine treatment of the nausea and
vomiting with antiemetics usually is ineffective in patients with CHS.
Narcotics do not relieve the abdominal pain but may cause worsening
rebound pain. The best treatment of CHS was found to be abstinence
from the use of marijuana (Allen et al., 2004; Simonetto et al., 2012;
Sun & Zimmerman, 2013).
It is important for advanced practice nurses to be able to
identify CHS as a potential differential in patients presenting to the
emergency department with recurrent nausea, vomiting, and
abdominal pain. They need to be knowledgeable about CHS to provide
the proper management of care for this specific medical condition.

Case Study
A 17-year-old adolescent boy entered the emergency
department with recurrent nausea and vomiting complaining of
epigastric abdominal pain. As he left triage in a wheelchair, provider
noticed that he appeared pale, his head was down inside a bucket, he
was diaphoretic, and he was making loud retching sounds. A nurse
stated, “This is the second time this week he's been here, he is
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nothing more than a drug seeker. He has been here two or three
times every week for the past 3 weeks.” His mother was with him,
and she appeared concerned and frustrated. She stated, “I want this
taken care of this time.” A review of his medical records indicated that
the last time he was seen in the emergency department he was
admitted as an inpatient with abdominal pain and dehydration. He
was just discharged the day before yesterday. The diagnosis on the
discharge summary was cyclic vomiting syndrome.
While interviewing the patient to obtain a history, he was asked
about marijuana use. He stated he smoked some yesterday, four to
five joints. He was discharged from the hospital 48 hr prior with no
nausea, vomiting, or abdominal pain (he was an inpatient for 48 hr).
The provider asked his mother whether she was aware that he has
been smoking marijuana, and she informed me that she was the
person who purchasing the marijuana (illegally) to help him with his
nausea and vomiting.
He was afebrile, tachycardic with a heart rate of 130 beats/min,
and blood pressure of 110/68 mmHg. Review his physical examination
and consider how would provider manage his plan of care?

Physical Examination
General
The patient was pale, diaphoretic, with dry mucous membranes
and pale skin.

Skin
Pale and warm to touch; the patient denied itching.

HEENT
PEERL. No fundoscopic abnormalities. Conjunctivae normal.
Nose clear without exudates or lesions. Mucous membranes pale and
dry. Tongue rugged. Slight erythema in posterior pharynx.

Heart
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No murmurs or rubs.

Lungs
No crackles or abnormal sounds bilaterally.

Abdomen
No guarding or rebound; abdomen soft and nondistended, with
normal bowel sounds.

Genitalia/Rectal
Stool in the rectum brown, heme negative.

Musculoskeletal/Extremities
Normal muscle strength in all extremities. Peripheral pulses 2+.
The patient denied any tenderness.

Neuro
A and O × 3. No focal weakness. Normal reflexes. Normal
coordination and gait.

Laboratory Test Results
The complete blood cell (CBC) count, the chemistry panel, and
the amylase and lipase were normal. Liver function tests were also
within normal limits.

Pharmacology Of Cannabis
The plant genus Cannabis contains 60 cannabinoids unique to
the plant. Delta-9-tetrahydrocannabinol (THC) is the most potent
psychoactive agent of the cannabis plant. Other plant cannabinoids
are cannabinol and cannabidiol. Cannabinoids are found in the stalks,
leaves, flowers, and seeds of the plant and also within the resin of the
female plant. Breeding techniques of the cannabis within the past 20
years has increased the potency of the plant. In 1960, a joint
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contained about 10 mg of THC, and today a joint contains about 150
mg of THC (Ashton, 2001).
When smoking a joint, 50% of the THC is inhaled, absorbed in
the lungs, and rapidly enters the bloodstream with a peak level
attained within 2 hr. Cannabis consumed orally reaches blood
concentrations of 25%–30% of that obtained from smoking. Onset
effect of the oral consumption is delayed by 0.5–2 hr because of the
slower absorption from the gut. Absorbed cannabinoids accumulate in
the fatty tissues of the body, reaching a peak in 4–5 days. Half-life of
THC is 7 days, and complete clearance takes approximately 30 days
(Ashton, 2001).

Disease Description and Pathophysiology
Cannabinoid hyperemesis syndrome is a disease caused by the
chronic use of cannabis. Consequently, some of the long-term users
develop recurrent (cyclic) events of nausea associated with violent
vomiting and colicky, cramping, epigastric, abdominal pain. These
symptoms may be relieved by taking a hot bath or hot shower;
however, when the hot bath or shower is completed, the symptoms
return. Three phases of the disease have been identified as the
prodromal, hyperemetic, and recovery phases. In the prodromal
phase, patients may experience some early morning nausea
associated with the sight or smell of foods; there may be some weight
loss associated with this phase. There is no compulsive bathing noted
during this phase. The hyperemesis phase is when the patient starts
to have profuse vomiting with the colicky, epigastric, abdominal pain.
It is during this period, the patient learns that the hot baths or
showers will help with the symptoms. It is also during this phase the
patients will visit the ED for management of the overwhelming
vomiting and retching. The recovery phase begins only when cannabis
use is stopped (Allen et al., 2004; Galli et al., 2011; Price, Fisher,
Kumar, & Hilgesson, 2011; Soriano-Co et al., 2010; Sun &
Zimmerman, 2013).
Tetrahydrocannabinol is the key component in cannabis, and it
affects the cannabinoid receptor system within the body. The
cannabinoid receptor system is involved in the physiological processes
of appetite, pain sensation, mood, and memory. Cannabinoid receptor
cells identified as cannabinoid receptor 1 (CB1) receptors are located
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mainly in the brain. CB1 receptors are also located within the
gastrointestinal system, within the enteric nervous system. The
effects of THC are mediated mainly by the CB1 receptors. It is the
CB1 receptors within the gastrointestinal tract that have an effect on
nausea, vomiting, and gastrointestinal inflammation (Galli et al.,
2011). CB2 receptors are located in the gastrointestinal systems as
well and only have an immune effect on the body (Galli et al., 2011;
Pertwee, 2001). Cannabis slows the motility of the gastrointestinal
tract, helping with nausea and vomiting, and is used medicinally for
this purpose (Galli et al., 2011).
Pertwee (2001) documented multiple studies conducted with
mice, rats, guinea pigs, and humans, showing the effects of THC on
the gastrointestinal tract. With prescribed doses of THC, an antiemetic
effect was found. However, pretreatment with a cannabinoid prior to
the prescribed dose caused a tolerance to the inhibitory effects of the
cannabinoid, provoking nausea, vomiting, and abdominal pain
(Pertwee, 2001). This may be the effect seen in the case of a chronic
marijuana user who exhibits hyperemesis and abdominal pain.
Another theory is that the toxicity of the CB1 and CB2 cells occurs
from the chronic use of THC (Simonetto et al., 2012)
Cannibidiol (CBD) and cannabigerol (CBG), two other
components of cannabis, appear to regulate the antiemetic properties
of THC. In animals, it was found that low doses of CBD and CBG had
an antiemetic effect on the animal; however, high doses of CBD and
CBG lead to vomiting (Galli et al., 2011).

Differentials for Cyclic Vomiting and Diagnostic
Criteria
The differentials for cyclic vomiting would include (but are not
exclusive to) hyperemesis gravidarum, bulimia, Addison's disease,
cyclic vomiting, psychogenic vomiting, or pancreatitis. Diagnostic
tests will help differentiate the diagnosis (see Table 1). Reviewing the
diagnostic studies of these 116 patients provides guidelines for
evaluation of the patients with recurrent vomiting.
Diagnostic criteria reviewed in the research conducted by Allen
et al. (2004), Soriano-Co et al. (2010), and Simonetto et al. (2012)
are documented in Table 2. The main laboratory tests that were done
Advanced Emergency Nursing Journal, Vol 37, No. 2 (April/June 2015): pg. 95-101. DOI. This article is © Lippincott
Williams & Wilkins, Inc. and permission has been granted for this version to appear in e-Publications@Marquette.
Lippincott Williams & Wilkins, Inc. does not grant permission for this article to be further copied/distributed or hosted
elsewhere without the express permission from Lippincott Williams & Wilkins, Inc.

6

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

were CBC count, basic chemistry, amylase, and a urine drug screen.
Soriano-Co et al. (2010) had eight patients in their study and of
these only one showed a leukocytosis on the CBC count. Two patients
had hypokalemia. The amylase level was normal for all eight
patients. Simonetto et al. (2012) identified 98 patients in their study.
All of the patients had a normal CBC count, chemistry, and amylase.
Allen et al. (2004) had 10 patients in their study and results of the
white blood cell count on the CBC count ranged from 11.5 to 16.9.
The basic chemistry showed normal potassium and sodium levels. All
10 patients had negative amylase levels. All 10 patients tested
positive for cannabis on the urine drug screen.
Abdominal ultrasonography was done in all of the studies.
Simonetto et al. (2012) reported that all of the ultrasonograms
showed normal findings. Allen et al. (2004) reported that nine of the
10 patients had abdominal ultrasonograms and all nine showed
normal findings. Soriano-Co et al. (2010) found fatty livers in 12.5%
of their patients.

Treatment
There is no documented evidence-based protocol for the
treatment of CHS. Information in the literature from case studies is
used as treatment guidelines (Hickey, Witsil, & Mycyk, 2013; Sun &
Zimmerman, 2013). Guidelines to follow initially when treating CHS
are to prevent dehydration, correct electrolyte deficiencies, and
relieve the nausea, vomiting, and abdominal pain. The patient should
be hydrated with a liter of normal saline. Any antiemetic agent can be
used for the presenting symptom of nausea and vomiting:
ondansetron (Zofran), metoclopramide (Reglan), promethazine
(Phenergan) with diphenhydramine (Benadryl), or prochlorperazine
(Compazine; Pareek, Fleisher, & Abell, 2007; Wallace, Andrews,
Garmany, & Jelley, 2011). Abdominal pain initially can be treated with
morphine or hydromorphone (Dilaudid). When the diagnostic test
results have returned and ruled out other potential causes of
recurrent vomiting and abdominal pain, the persistent symptoms
need to be addressed. In most cases of CHS, the diagnostic test
results show normal findings (see Table 2). The persistent symptoms
now need to be addressed.
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Hickey et al. (2013) identified a patient with CHS in their ED;
initially, they treated him with a liter of saline, ondansetron (Zofran) 4
mg intravenously and a single dose of hydromorphone (Dilaudid) for
his abdominal pain. All of his diagnostic laboratory results showed
normal findings, and his symptoms persisted. It was decided that the
patient's symptoms persisted at the same level 1 hr after treatment;
therefore, a dose of haloperidol (Haldol) 5 mg intravenously was
tried. After reviewing anesthesia literature related to nausea and
vomiting postoperatively, it was noted that haloperidol worked;
therefore, in this case of CHS, Hickey et al. (2013) tried a dose of
haloperidol (Haldol) 5 mg intravenously. Within 1 hr, all of the
symptoms subsided and the patient with CHS was discharged home
with instructions to stop using marijuana.
Pareek et al. (2007) reviewed literature of case studies related
to CHS and determined that treatment of CHS should include either
ondansetron (Zofran) 4 mg intravenously or promethazine
(Phenergan) 25 mg intravenously with diphenhydramine (Benadryl)
25–50 mg intravenously. If this treatment of nausea and vomiting
did not work, it was recommended to use any benzodiazepine to
promote sleep, which was found to stop the acute episode of
vomiting. The benzodiazepine they identified in their article was
lorazepam 1 mg intravenously and it could be repeated every 4 hr as
needed. A summary of treatment options for the hyperemetic phase
are given in Table 3.

Conclusion
The patient in our case study did receive Zofran (ondansetron)
4 mg intravenously for his nausea and Ativan (lorazepam) 1 mg for
his abdominal pain along with a liter of fluid. When the laboratory
results were reviewed, the likely cause of symptoms was explained to
the patient. It was discussed that when he was an inpatient in the
hospital, he was not using marijuana and his symptoms improved;
however, when he went home and began smoking marijuana joints,
all of the symptoms returned with a higher intensity. His mother then
verbalized her understanding of the situation and wanted to better
understand why marijuana used for nausea medicinally was not
working for her son. Educating patients about recreational and over-

Advanced Emergency Nursing Journal, Vol 37, No. 2 (April/June 2015): pg. 95-101. DOI. This article is © Lippincott
Williams & Wilkins, Inc. and permission has been granted for this version to appear in e-Publications@Marquette.
Lippincott Williams & Wilkins, Inc. does not grant permission for this article to be further copied/distributed or hosted
elsewhere without the express permission from Lippincott Williams & Wilkins, Inc.

8

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

the-counter medication, effects, and side effects is a key component
of discharge teaching.
It is important for advanced practice nurses to be able to
identify CHS in their differentials of patients presenting to the ED with
recurrent nausea, vomiting, and abdominal pain. They need to be
knowledgeable about CHS to provide the proper management of care
for this specific medical condition.
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Table 1. Differential diagnoses
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Table 2. Literature review: diagnostic results for cannabinoid hyperemesis

Table 3. Treatment options: hyperemetic phase of cannabinoid hyperemesis
syndrome
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